Dużo type of report	**Current report**
number	70/2013
company	PHARMENA

Obtaining authorisation for phase II clinical trials of anti-atherosclerosis medicinal product 1-MNA

With reference to the Company's Strategy for 2012-2015 (published in current report no. 16/2012 of 13th April 2012) and the communication on filing to Health Canada for granting permission to phase II clinical trials of anti-atherosclerosis medicinal product 1-MNA (published in current report no. 51/2013 of 16th July 2013), the Management Board of PHARMENA S.A. informs that on 7th October 2013, the subsidiary company Cortria Corporation (USA) received notification that Health Canada (an authority supervising clinical trials in Canada) granted its permission ("Notice of Authorization") for conducting phase II clinical trials ("Proof of Concept") over the innovative anti-atherosclerosis medicinal product based on 1-MNA active substance (working name of the product – TRIA-662). Health Canada granted its permission to conduct the trials in line with the form proposed by Cortria Corporation.

Phase II clinical trials ("Proof of Concept") over the TRIA 662 medicinal product will be randomised, multi-centred, placebo controlled, with total participation of at least 64 subjects (two control groups: 1-MNA, placebo, ratio: 3:1). Key inclusion criteria for subjects' inclusion in the trial shall be: TG > 200 mg/dl (2.26 mmol/l) and < 500 mg/dl (5.65 mmol/l) levels as well as HDL-C < 40 mg/dl (1.0 mmol/L) level in men and < 50 mg/dl (1.3 mmol/L) level in women. The actual clinical trial will be preceded by a 6-week period, when 200 subjects will be subjected to controlled diet. After this time randomisation will take place, i.e. random selection of at least 64 subjects from the group of subjects subjected to the controlled diet. Randomly selected subjects who fulfil the inclusion criteria will participate in the actual clinical trial, in which 1-MNA medicinal product will be administered to them. Medicinal product will be administered 3 times a day, with a meal, for the period of 14 weeks. Key parameters of lipid profile will be controlled (i.e. TG, HDL, LDL and TC levels), inflammation (CRP, IL6) and parameters related to the safety of the medicinal product (i.e. glucose, ALT, ASP, electrocardiogram). Upon completion of the trial a report containing trial results will be issued.

The aim of the trial is to establish the effective dose of the medicinal product and to confirm the lack of side effects in humans in higher doses. Planned time scope for the trial is 12 months from the date of obtaining permission from Health Canada market regulator. The supervisory institution will be Montreal Heart Institute, and participation of ca. 15 clinics in the trial is planned.

Montreal Heart Institute is a leading research centre in Canada, specialising in cardiology, and one of the largest institutes of this type in the world. It is a world renown Institute, that has introduced many innovatory solutions nationally and world-wide. For more information see www.icm-mhi.org.

Phase II clinical trial ("Proof of Concept") is planned to be financed from funds raised in issue of series D shares. Subsequent current reports issued by the Company will inform on progress of research and trials of the 1-MNA innovative anti-atherosclerotic medicinal product.

This information was issued, since conducting phase II clinical trial is necessary for commercialisation of 1-MNA anti-atherosclerotic medicinal product project, while potential revenues on the medicinal product commercialisation may have very significant impact on financial results and market valuation of the Issuer.

Legal basis: Alternative Trading System Rules – Exhibit 3 "Current and Periodical Information in the Alternative Trading System on the NewConnect Market", Article 3 (2.2)".

Representatives of the company:

- Konrad Palka – President of the Board
- Marzena Wieczorkowska – Vice President of the Board